Investors who want to find high-quality med-tech names trading at
meaningful discounts are going to have to hunt around, as there aren't a
lot of obvious bargains on the high-quality shelves. Stryker (NYSE:SYK)
remains a well-run and diversified med-tech player, and one with the
flexibility to pursue value-creating M&A, but it's not trading at a
valuation that would suggest that its prospects are overlooked by the
market. I wouldn't sell the shares if I owned them, and there are worse
things than buying a very good company at a fair price, but I can't call
it a must-buy at this price.
Continue here for more:
Stryker Offers Good Core Growth, But Not As Much Value
No comments:
Post a Comment